Invention Grant
- Patent Title: Non-integrative listeria-based vaccine and method for inducing antitumor immune response
-
Application No.: US17050666Application Date: 2019-04-23
-
Publication No.: US11648306B2Publication Date: 2023-05-16
- Inventor: Nan Dai , Yonggang Zhao
- Applicant: Suzhou RoyalTech Med CO., Ltd , Shanghai RoyalTech Med CO., Ltd
- Applicant Address: CN Suzhou
- Assignee: Suzhou RoyalTech Med CO., Ltd,Shanghai RoyalTech Med CO., Ltd
- Current Assignee: Suzhou RoyalTech Med CO., Ltd,Shanghai RoyalTech Med CO., Ltd
- Current Assignee Address: CN Suzhou; CN Shanghai
- Agency: Fish & Richardson P.C.
- Priority: CN 1810392619.X 2018.04.27
- International Application: PCT/CN2019/083815 2019.04.23
- International Announcement: WO2019/206116A 2019.10.31
- Date entered country: 2020-10-26
- Main IPC: A61K39/385
- IPC: A61K39/385 ; A61P35/00 ; A61K39/00 ; A61K39/02 ; A61K45/06 ; C07K14/195 ; C07K14/47 ; C07K14/77
Abstract:
Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.
Public/Granted literature
- US20210308260A1 Non-integrative Listeria-based vaccine and method for inducing antitumor immune response Public/Granted day:2021-10-07
Information query
